Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T17:06:42.774Z.
Calculation as of: 2026-10-06T17:06:42.774Z.
Quote observation: 2026-10-06T17:05:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e7bb4fe4bb3aa983eb4620adc8aa5d0f555a5020ff21ce65ee2b72f9631e0f85
PE RATIO
N/A
Market Cap
$2.67B
PE Ratio
9.71
TTM Avg
24.39
3Y Avg
82.90
5Y Avg
82.90
Market Cap
$2.67B
PE Ratio
N/A
TTM Avg
12.43
3Y Avg
16.75
5Y Avg
20.41
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | $2.83B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.81B | 21.07 | 33.77 | 471.31 | 471.31 |
| AtriCure, Inc. (ATRC)vs › | $2.79B | 258.25 | 234.61 | 234.61 | 81.83 |
| Precigen, Inc. (PGEN)vs › | $2.71B | N/A | 14.11 | 14.11 | 14.11 |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.67B | 9.71 | 24.39 | 82.90 | 82.90 |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.67B | N/A | 12.43 | 16.75 | 20.41 |
| MBX Biosciences, Inc. Common Stock (MBX)vs › | $2.67B | N/A | N/A | N/A | N/A |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.00B | N/A | N/A | N/A | N/A |
| Neogen Corporation (NEOG)vs › | $2.66B | N/A | 1199.59 | 405.60 | 257.67 |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.02B | 115.73 | 121.55 | 121.55 | 121.55 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$15.15
Forward EPS (Est.)
$-3.63
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
